Predicting Anthracycline Benefit: TOP2A and CEP17—Not Only but Also | Zendy

John M.S. Bartlett | Zendy; Christopher C. McConkey | Zendy; Alison F. Munro | Zendy; Christine Desmedt | Zendy; Janet Dunn | Zendy; Denis Larsimont | Zendy; Frances P. O’Malley | Zendy; David Cameron | Zendy; Helena Earl | Zendy; Christopher Poole | Zendy; Lois E. Shepherd | Zendy; Fátima Cardoso | Zendy; MajBritt Jensen | Zendy; Carlos Caldas | Zendy; Christopher Twelves | Zendy; Daniel Rea | Zendy; Bent Ejlertsen | Zendy; Angelo Di Leo | Zendy; Kathleen I. Pritchard | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Predicting Anthracycline Benefit: TOP2A and CEP17—Not Only but Also

Author(s) -

John M.S. Bartlett,

Christopher C. McConkey,

Alison F. Munro,

Christine Desmedt,

Janet Dunn,

Denis Larsimont,

Frances P. O’Malley,

David Cameron,

Helena Earl,

Christopher Poole,

Lois E. Shepherd,

Fátima Cardoso,

MajBritt Jensen,

Carlos Caldas,

Christopher Twelves,

Daniel Rea,

Bent Ejlertsen,

Angelo Di Leo,

Kathleen I. Pritchard

Publication year - 2015

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2013.54.7869

Subject(s) - anthracycline , medicine , oncology , hazard ratio , fluorescence in situ hybridization , chemotherapy , cyclophosphamide , breast cancer , cancer , biology , genetics , chromosome , confidence interval , gene

Evidence supporting the clinical utility of predictive biomarkers of anthracycline activity is weak, with a recent meta-analysis failing to provide strong evidence for either HER2 or TOP2A. Having previously shown that duplication of chromosome 17 pericentromeric alpha satellite as measured with a centromere enumeration probe (CEP17) predicted sensitivity to anthracyclines, we report here an individual patient-level pooled analysis of data from five trials comparing anthracycline-based chemotherapy with CMF (cyclophosphamide, methotrexate, and fluorouracil) as adjuvant chemotherapy for early breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research